Sen. Grassley Presses HHS OIG to Punish Drug Makers Over Denials of 340B Pricing

Sen. Chuck Grassley (R-IA) headshot
U.S. Sen. Chuck Grassley (R-Iowa) wants to know if HHS will impose civil monetary penalties on drug companies that deny 340B pricing over multiple contract pharmacy.

Senate Finance Committee ranking Republican Chuck Grassley (Iowa) yesterday asked the U.S. Health and Human Services Department of Inspector General (OIG) if it plans to punish seven drug companies over their denials of 340B pricing when hospitals, health centers, and

Read More »

Sen. Manchin Endorses 340B Ally McKinley in Tight GOP Primary Race

Sen. Joe Manchin (D-WV) and Rep. David McKinley (R-WV) headshots
Conservative Democratic U.S. Sen. Joe Manchin has endorsed moderate Republican Rep. David McKinley in West Virginia's GOP congressional primary election next week against Rep. Alex Mooney, who is backed by ex-President Trump.

Conservative Democratic U.S. Sen. Joe Manchin (W.Va.) has endorsed and appeared in a campaign advertisement for Republican Rep. David McKinley (W.Va.), a moderate being challenged for re-election by a candidate endorsed by ex-President Donald Trump.

The GOP primary between McKinley

Read More »

With Retired Sen. Hatch’s Passing, a Legendary 340B Tale is Told

Sen. Orrin Hatch headshot
Retired U.S. Sen. Orrin Hatch (R-Utah), who died this weekend, played a key role in 340B's creation and development.

Retired U.S. Sen. Orrin Hatch of Utah, a conservative Republican icon who helped create and shape the 340B drug pricing program, has died. He was 88.

Hatch personally was responsible for choosing one of the 340B program’s most important covered

Read More »

73 Groups Want Congress to Enact Major Drug Pricing Reforms by Memorial Day

Push for Lower Rx Prices organization wordmark
Seventy three organizations, under the banner Push for LowerRx Prices, launched a campaign to press Congress to pass comprehensive Democratic drug pricing legislation by Memorial Day.

More than 70 groups representing patients, healthcare professionals, consumers, retirees, employers, and unions launched a campaign this morning to get comprehensive Democratic drug pricing legislation signed into law by Memorial Day.

It is premature to guess how the final version

Read More »

48 Hospitals Seek Readmission to 340B After Losing Eligibility Due to COVID-19 Pandemic

health care workers in hazmat suits with COVID-19 patient
Forty eight hospitals that lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic are seeking reinstatement to the 340B program.

At least 48 hospitals lost their eligibility for 340B drug discounts for reasons related to the COVID-19 pandemic and are seeking reinstatement to the 340B program, the U.S. Health Resources and Services Administration (HRSA) said this week.

April 14

Read More »

Harvard Drug Policy Experts Write in JAMA About How Congress Could Fix 340B Contract Pharmacy Mess

screenshot of 340B drug pricing program article in JAMA
"Contract pharmacy restrictions are the latest problem with implementation of the 340B program that threaten to undermine its laudable goals," three Harvard drug policy experts say in an opinion article in JAMA.

A nationally prominent drug policy expert and two colleagues at Harvard Medical School have written in JAMA how Congress could end the fight over 340B contract pharmacy and enhance 340B program integrity.

“First, Congress could explicitly allow the participation of

Read More »

Virginia Governor Signs 340B Anti-Discrimination Bill for Grantees

Gov. Glenn Youngkin signing legislation with supporters

Virginia Gov. Glenn Youngkin (R) yesterday signed legislation to stop insurers and their pharmacy benefit managers (PBMs) from discriminating against 340B grantee covered entities and their contract pharmacies. Hospitals are excluded from protection.

The new law takes effect July 1.

Read More »

340B Report Publisher and CEO Slafsky: 340B Contract Pharmacy Program Has Fractured Into 17 Pieces

shattered glass
Drug manufacturers' 340B contract pharmacy actions have seemingly fractured the 340B program into pieces, 340B Publisher and CEO Ted Slafsky says.

“The 340B contract pharmacy program has seemingly fractured into 17 programs, one governed by the federal government and 16 others with their own standards determined by pharmaceutical manufacturers,” 340B Publisher and CEO Ted Slafsky observes in his latest column for

Read More »

Influential 340B Lawmaker Upton Announces Retirement

Rep. Fred Upton speaks at a House hearing
U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, is retiring from Congress.

U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, announced on Tuesday he will not seek another term in Congress.

“Even the best of stories has a last chapter,”

Read More »

Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion

Institute for Clinical and Economic Review wordmark
Policymakers should consider narrowing the 340B orphan drug exemption, ICER said today in a new report.

The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live